NCT05194995 2026-03-16JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationAllist Pharmaceuticals, Inc.Phase 1/2 Active not recruiting48 enrolled